E. Magherini

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

Judith Hugh, John Hanson, Maggie C.U. Cheang et al. · Journal of Clinical Oncology · 2009 · 533 citations · Full text

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Ian F. Tannock, Karim Fizazi, Camilla Thellenberg Karlsson et al. · The Lancet Oncology · 2013 · 285 citations

Aflibercept Versus Placebo, Urology, Oncology +7

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy, B Paillot, Éric François et al. · Journal of Clinical Oncology · 2005 · 239 citations

Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand

Florian Scotté, Jean‐Marc Tourani, Eugéniu Banu et al. · Journal of Clinical Oncology · 2005 · 193 citations

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level

Valérie Boige, Mohamed Hebbar, David Malka et al. · European Journal of Cancer · 2006 · 65 citations

Dose Adjustment, Oncology, Hepatology +11